Dr. Conrad Ziembinski, MD
Rheumatology (Rheumatology Physician)
- Medicare participating
At a glance
- Medical school
- At Still Un of Hlth Sciences, Col of Osteo Med, Mesa (2016)
- Years since graduation
- 10
- In the NPI registry since
- 2016
- Medicare patients seen, 2024
- 238
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2016Medical school: At Still Un of Hlth Sciences, Col of Osteo Med, Mesa
- 2016Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Rheumatology Physician primary
FL license OS15342
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mount Sinai Medical Center of Florida, Inc Miami Beach, FL
- Broward Health Coral Springs Coral Springs, FL
Medical groups
- American Arthritis and Rheumatology Associates LLC (65 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 238
- Services billed
- 56,930
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, romosozumab-aqqg, 1 mg | 24,150 | 19 |
| Injection, denosumab, 1 mg | 4,500 | 49 |
| Established patient office or other outpatient visit, 30-39 minutes | 290 | 152 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 266 | 64 |
| Administration of chemotherapy into vein, 1 hour or less | 142 | 26 |
| New patient office or other outpatient visit, 60-74 minutes | 81 | 81 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 60 | 17 |
| Insertion of needle into vein for collection of blood sample | 52 | 38 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 21 companies reported 167 payments worth $3,644 in total to this clinician.
| Food and Beverage | $3,644 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 6 companies. The companies reported $134,574 in research payments for these studies, mostly to the institutions running them.
- A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-1)
E.r. Squibb & Sons, L.l.c. - Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patie…
Argenx US, Inc. - M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE)
AbbVie Inc. - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
AbbVie Inc. · Active, not recruiting · NCT05843643 - A phase 4, prospective, open-label, single-arm study to assess the effectiveness of tirzepatide after initiation of ixekizumab in adult participants with active psoriatic arthritis and overweight or obesity in clini…
Eli Lilly and Company - Phase 2 Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
Alexion Pharmaceuticals, Inc. - LUPKYNIS Registry Study
Aurinia Pharma U.S., Inc. - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
AbbVie Inc. · Completed · NCT05814627
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.